Cure8 research brief
The findings suggest that early biologic and immunomodulator treatment may reduce the need for first surgery in Crohn's disease, which is directly relevant to treatment planning and expectations for people with IBD.
Adult patients with Crohn's disease (especially newly diagnosed or higher-risk patients), clinicians managing IBD, and researchers studying treatment timing and surgical outcomes.
This retrospective cohort of 153 Crohn's patients (2009–2023) reported cumulative probabilities of surgery of 3% at 1 year, 11% at 5 years, and 34% at 10 years.
In multivariable modeling, early biologic therapy had the strongest association with reduced time to first surgery, followed by colonic disease location, inflammatory (non-stricturing, non-penetrating) phenotype, diagnosis in the biologic era (≥2017), and early azathioprine initiation.
The authors interpret these as additive protective effects of early combined therapy for higher-risk patients.
This is a retrospective cohort from a single center; observed associations may be influenced by treatment selection, era effects, and local practice patterns. The content is grounded in the article abstract rather than a full independent review.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The review links specific therapies and surgical options to outcomes that matter to people with IBD — mucosal healing, lower hospitalizations, and reduced need for surgery — and highlights that combining medical and...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
Because intestinal lymphoma can closely mimic Crohn’s disease, recognizing red flags (severe malabsorption, proximal small-bowel involvement, monoclonal gammopathy, poor response to IBD therapy) can change diagnosis and...
